Optimal Stent Deployment Strategy of Contemporary Stents (PERFECTPSP)
OPtimal stEnt Deployment stRategy oF Contemporary sTents
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Rationale: Historically, when coronary stents were initially introduced, the standard and mandatory treatment of a significant stenosis was with pre-dilation prior to stent placement. In the 2000s, several studies found no significant difference in clinical outcome between the two different stent implantation techniques: direct stenting (DS) versus the conventional stenting after pre-dilation (CS). Consequently, the stent implantation technique has become "unprotocolarised", i.e. each operator has their own, individual set of reasons for applying or avoiding pre- and post-dilation in specific conditions. However, these trials do not apply to the current/modern clinical practice of coronary stenting. The current patient population undergoing percutaneous coronary intervention (PCI) cannot be compared to the population that was treated in the early 2000s. The same applies for stent design. Stents have undergone several major transformations in the last 20 years. Furthermore, the events rates after PCI have significantly decreased within the last decades due to better stent design and improved background pharmacological therapy.
Imaging studies have revealed that an optimal stent result is not achieved in a high percentage of stent implantations. Post-hoc studies have demonstrated that the optimization of the implantation technique could reduce adverse cardiac events over time. As a result of these findings, the PSP concept: Pre-dilation, Sizing and Post-dilation was introduced. Whether routine pre- and postdilatation compared to DS also results in optimal stent implantation in contemporary drug-eluting stents (DES) has not been investigated and, hence is currently unknown.
Objective: The primary objective is to evaluate whether a standard pre- and postdilatation (PSP strategy) of the modern DES results in a more optimal stent implantation compared to DS as evaluated by OCT in patients with stable coronary artery disease. The secondary clinical objective is to evaluate clinical cardiovascular outcomes in patients with stable coronary artery disease treated with the PSP strategy.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Selina Vlieger, MSc
- Phone Number: 0786541492
- Email: s.vlieger@asz.nl
Study Locations
-
-
-
Dordrecht, Netherlands
- Recruiting
- Albert Schweitzer Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Stable angina patients or acute coronary syndrome patients with bystander stable coronary artery disease
With one or more significant epicardial stenosis in native coronary arteries suitable for direct stenting, according to the judgement of treating operator.
The use of fractional flow reserve (FFR) or resting indices like iFR and RFR to assess lesion severity is encouraged.
- Subject must be at least 18 years of age
- Written consent to participate in the study
Exclusion Criteria:
- Lesions not suitable for direct stenting, like (sub)-total stenosis, severely calcified lesions
- Culprit lesions of acute coronary syndrome cannot be randomized to the trial. After successful treatment of the ACS culprit lesion, patients however can be randomized in the trial in case of remaining stable non-culprit lesions that thought to be stented directly of during a staged procedure.
- Lesions not suitable for OCT catheter delivery and imaging, e.g. left main or ostial right coronary artery stenosis, lesions in coronary bypass grafts or tortuous anatomy
- Treatment for in-stent restenosis
- Bifurcation lesions in which a two-stent technique or a proximal postdilatation is planned.
- Treatment of coronary artery bypass grafts
- Creatine Clearance ≤ 30 ml/min/1.73 m2 (as calculated by MDRD formula for estimated GFR)
- Known hypersensitivity or allergy for cobalt chromium
- Known comorbidity associated with a life expectancy < 1 year
- Unable to understand and follow study-related instructions or unable to comply with study protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: PSP technique
The definitions of the PSP technique are:
|
percutaneous coronary intervention
|
|
Active Comparator: Direct Stenting
• The DES is directly placed without any lesion preparation and deployed at a pressure at the discretion of the operator.
Ideally a pressure would be achieved in which angiographic expansion of the DES is complete (without significant dog-boning)
|
percutaneous coronary intervention
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Suboptimal stent results which is defined as a composite of major stent underexpansion and major edge dissection measured by OCT at lesion level directly after completion of the stent implantation according to the protocol
Time Frame: During procedure
|
Stent malapposition (categorical variable) is defined as:
Edge dissections (categorical variable) will be presented as: • Dissections on OCT of ≥60 degrees of the circumference of the vessel at the site of dissection and ≥3 mm in length |
During procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
MACE
Time Frame: 1-,3- and 5-year follow-up
|
a composite of time- to-first event rate of cardiac death, target vessel MI, ischemia-driven target vessel revascularization (TVR)
|
1-,3- and 5-year follow-up
|
|
Target Lesion Failure (TLF)
Time Frame: 1-,3- and 5-year follow-up
|
defined as cardiac death, target vessel- myocardial infarction and clinically indicated target lesion revascularization)
|
1-,3- and 5-year follow-up
|
|
Target Vessel Failure (TVF)
Time Frame: 1-,3- and 5-year follow-up
|
defined as cardiac death, target vessel- myocardial infarction and clinically indicated target vessel revascularization
|
1-,3- and 5-year follow-up
|
|
All cause mortality
Time Frame: 1-,3- and 5-year follow-up
|
1-,3- and 5-year follow-up
|
|
|
Cost-effectiveness analysis
Time Frame: 1-,3- and 5-year follow-up
|
total number of stent, balloons, wires and repeat hospitalizations due to MACE
|
1-,3- and 5-year follow-up
|
|
Minimal stent area (MSA) (mm^2)
Time Frame: During procedure
|
During procedure
|
|
|
Acute recoil (percent)
Time Frame: During procedure
|
assessed on coronary angiography
|
During procedure
|
|
Stent malapposition (percent)
Time Frame: During procedure
|
defined as frequency of incompletely apposed stent struts (defined as stent struts clearly separated from the vessel wall (lumen border/plaque surface) without any tissue behind the struts with a distance from the adjacent intima of ≥0.2 mm and not associated with any side branch).
|
During procedure
|
|
Mean stent expansion (percent):
Time Frame: During procedure
|
mean stent area (stent volume/analysed stent length) divided by the average of proximal and distal reference lumen areas x 100
|
During procedure
|
|
Intra-stent plaque protrusion and thrombus
Time Frame: During procedure
|
defined as any intraluminal mass protruding at least 0.2 mm within the luminal edge of a stent strut
|
During procedure
|
|
Post OCT stent result optimalization (percent)
Time Frame: During procedure
|
composite of additional post-dilation and/or stent placements after OCT
|
During procedure
|
|
Stent Thrombosis
Time Frame: 1-,3- and 5-year follow-up
|
definite or probable; Academic Research Consortium (ARC) definition
|
1-,3- and 5-year follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Rohit Oemrawsingh, MD, PhD, Albert Schweitzer Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PERFECT 001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.